Table 1 Literature values for terminal survival half-life (t½) of SARS-CoV-2 on prototypic HITES, on skin, or in suspension.

From: Microbicidal actives with virucidal efficacy against SARS-CoV-2 and other beta- and alpha-coronaviruses and implications for future emerging coronaviruses and other enveloped viruses

Prototypic fomite/suspension

Organic load

Temperature (RH)

Survival t½ (h)

Time needed for 1 log10 reduction in titer (h)

Time needed to decrease viral burden below MID (h)a

References

Plastic

None

21–23 °C (40%)

6.8

23

91

15

None

22 °C (65%)

11

37

147

14

None

25–27 °C (35%)

16

53

213

20

None

19–21 °C (45–55%)

35

115

460

16

10 mg/mL BSA

19–21 °C (45–55%)

24

79

316

16

Human sputum

21 °C (40%)

3.1

10

40

17

Human mucus

21 °C (40%)

3.1

10

40

17

Tripartite soil

20 °C (35–40%)

38

130

520

18

Stainless steel

None

21–23 °C (40%)

5.6

19

75

15

None

22 °C (65%)

15

50

200

14

None

25–27 °C (35%)

23

77

306

20

Tripartite soil

20 °C (35–40%)

29

95

380

18

Tripartite soil

20 °C (50%)

43

143

573

21

Aluminum

None

19–21 °C (45–55%)

0.33

1.1

4.4

16

10 mg/mL BSA

19–21 °C (45–55%)

15

51

204

16

Glass

None

22 °C (65%)

4.8

16

64

14

None

25–27 °C (35%)

22

73

293

20

None

19–21 °C (45–55%)

7.0

23

93

16

10 mg/mL BSA

19–21 °C (45–55%)

25

83

333

16

Tripartite soil

20 °C (50%)

46

153

613

21

Wood

None

22 °C (65%)

0.71

2.4

9.5

14

None

25–27 °C (35%)

21

70

280

20

Vinyl

Tripartite soil

20 °C (50%)

46

153

613

21

Copper

None

21–23 °C (40%)

0.77

2.6

10

15

Cardboard

None

21–23 °C (40%)

3.5

12

47

15

Liquid sputum

N/A

21 °C

1.9

6.3

25

17

Liquid mucus

N/A

21 °C

3.7

12

47

17

Swine skin

None

20–24 °C (40–50%)

3.5

12

47

19

Human feces (10% suspension)

None

25–27 °C (35%)

2.6

8.7

35

20

Human urine

None

25–27 °C (35%)

16

53

212

20

  1. Abbreviations used: BSA, bovine serum albumin; MID, human minimal infectious dose; RH, relative humidity; t½, half-life.
  2. aCalculated assuming an initial deposited virus burden of 1.0 × 106 plaque-forming units (PFU) and an estimated human MID of 250 PFU (see “Methods” section).